Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

Autor: Gross-Goupil, M., Kwon, T.G., Eto, M., Ye, D., Miyake, H., Seo, S.I., Byun, S.-S., Lee, J.L., Master, V., Jin, J., DeBenedetto, R., Linke, R., Casey, M., Rosbrook, B., Lechuga, M., Valota, O., Grande, E., Quinn, D.I. ^*

Publikováno v: In Annals of Oncology December 2018 29(12):2371-2378

Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial.

Autor: Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. motzerr@mskcc.org., Martini JF; Global Product Development-Oncology, Pfizer Inc, La Jolla, CA, 92121, USA., Mu XJ; Oncology Research Unit, Pfizer Worldwide Research and Development Medicine, Pfizer Inc, La Jolla, CA, 92121, USA., Staehler M; Department of Urology, University Hospital of Munich, Munich, Bavaria, 80333, Germany., George DJ; Department of Medicine, Duke Cancer Institute, Durham, NC, 27710, USA., Valota O; Global Product Development-Oncology, Pfizer S.r.L, Milan, Lombardy, 20152, Italy., Lin X; Global Product Development-Oncology, Pfizer Inc, La Jolla, CA, 92121, USA., Pandha HS; Department of Medical Oncology, University of Surrey, Guildford, England, GU2 7XS, UK., Ching KA; Oncology Research Unit, Pfizer Worldwide Research and Development Medicine, Pfizer Inc, La Jolla, CA, 92121, USA., Ravaud A; Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, 33300, France.

Publikováno v: Nature communications [Nat Commun] 2022 Oct 10; Vol. 13 (1), pp. 5959. Date of Electronic Publication: 2022 Oct 10.

Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours

Autor: de Jonge, M.J.A., Verweij, J., van der Gaast, A., Valota, O., Mora, O., Planting, A.S.Th., Mantel, M.A., Bosch, S.Van Den, Lechuga, M.J., Fiorentini, F., Hess, D., Sessa, C.

Publikováno v: In European Journal of Cancer December 2002 38(18):2407-2415

906PD - Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Comprehensive tumour genomic and transcriptomic analyses

Autor: Ravaud, A., Martini, J.-F., Ching, K., Staehler, M., Magheli, A., Escudier, B., Mu, X.J., Valota, O., Lin, X., Motzer, R.J.

Publikováno v: In Annals of Oncology October 2019 30 Supplement 5:v358-v359

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.

Autor: Michaelson MD; Claire and John Bertucci Center for Genitourinary Cancers, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA dmichaelson1@mgh.harvard.edu., Gupta S; Masonic Cancer Center, Minneapolis, Minnesota, USA., Agarwal N; Huntsman Cancer Institute, Salt Lake City, Utah, USA., Szmulewitz R; University of Chicago, Chicago, Illinois, USA., Powles T; Barts Cancer Institute, London, UK., Pili R; Indiana University, Indianapolis, Indiana, USA., Bruce JY; University of Wisconsin, Madison, Wisconsin, USA., Vaishampayan U; Karmanos Cancer Center, Detroit, Michigan, USA., Larkin J; The Royal Marsden, London, UK., Rosbrook B; Pfizer Oncology, San Diego, California, USA., Wang E; Pfizer Oncology, San Diego, California, USA., Murphy D; Pfizer Oncology, San Diego, California, USA., Wang P; Pfizer Oncology, Shanghai, People's Republic of China., Lechuga MJ; Pfizer Oncology, Milan, Italy., Valota O; Pfizer Oncology, Milan, Italy., Shepard DR; Cleveland Clinic, Cleveland, Ohio, USA.

Publikováno v: The oncologist [Oncologist] 2019 Sep; Vol. 24 (9), pp. 1151-e817. Date of Electronic Publication: 2019 Jun 06.